www.gavi.org
COVAX: KEY STRATEGIC
ISSUES
BOARD MEETING
Aur?lia Nguyen, Marie -Ange Saraka -Yao,
Thabani Maphosa
28 September 2021, Virtual Meeting
Agenda
1. COVAX Update and 2022 Vision
2. Update on Brokerage, Resell and Exchange
3.
4.
Update on SFP2.0
COVAX Delivery Update
5. COVAX Resource Mobilisation Update
6. Discussion
Board meeting
28 September 2021

Gavi

Bo ard -2021-Mt g-3-Doc 0 1a




Gavi Alliance Board Meeting
28 September 202 1
Virtual Meeting
Quorum: 1 4
Declarations of Interest

Declarations
Section 5.5 of the Conflicts of Interest Policy for Governance Bodies states ?Members
involved in decisio n-makin g processes on b eha lf of Gavi must take appropriate action to
ensure disclosure of Interests and Conflicts of Inter est, and take the necessary action in
respect thereof.?
Section 6.2 of the Conflicts of Interest Policy for Governance Bodies further states , ?T he duty
to d isc lose [in 6.1 above] is a continuing obligation. This means that Members are obliged to
disclose any Interests and/or Conflict of Interest, whenever the Member comes to know the
relevant matter.?
The following declarations were made b y me mbers of the Bo ard on their most recent annual
statements .
Board members:
Member Org anisational Interest s

Financial/Personal/Advisor Int /
Others














Jos? Manuel Barroso , Chair




























None














Goldman Sachs I nter national
(Chairman and Non -Executive
Director -Advisor ); Princeton
University - Princeton School of
Public Policy, LISD, (Non
Residen t Fellow ); Catholic
Unive rsity o f Portugal (Visiting
Professor ); Centre fo r Euro pean
Stu die s (Director) ; Graduate
Insti tute of International and
Development Studies -Geneva,
(Visiting Professor ); The
EUROPEAUM (Board Member );
WPL -Women Political Leaders
(Advisory Board Member ); Je an
Monn et Foundation for Europe
(Honorary Committee Member );
Eur ope an C entre for C ulture,
(Honorary Co -President );
Portuguese Diaspora Council
(Chairman General Assembly );
Bilderberg Meetings (Steering
Committee Member ); Concordia
(Leade rship Member Council );
Wo rld Lea dership Alliance - Club
de Madrid (Member ); Teatro Real
Ma drid (Internation al Council
member ); Royal Institute of
International Affairs (Chattam

Board -2021-Mtg-3-Doc 00b
Classified as Restricted




G avi Alliance Board Meeting
28 September 2021 , Virtual Meeting

Tuesday 28 September : 14.00 -18.30 Geneva Time
Quorum: 14

A genda revised

Item Sub ject Action Schedule

1 Chair?s report
? Declarations of interest
Jos ? Manuel Barroso , Board Chair
14.00 -14. 15
2 Introductory remarks: CEO
Seth Berkley, Chief Executive Officer
14 .15 -14.25
3 Gavi 5 .0: An overview of key issues
Anura dha Gupta, Depu ty C EO
14.25 -14.45
Discussion and Q &A 14.45 -15. 30
Break 15.30 -15.45
4 COVAX : Key Strategic Issue s (incl. reports from Co-Chairs of
COVAX AMC Engage ment Group and COVAX Share holders
Council )
Aur ?lia Nguyen, Managing Director , Offi ce of the COVAX Facility ;
Marie -Ange Saraka Yao, Managing Di rector, Re sou rce
Mobilisation, Private Sector Partnerships & In novative Finance
15.45 -18.15
5 Closing remarks
Jos ? Manu el Barroso , Board Chai r
18.1 5-18.30

Ne xt Board Meeting s: 1-2 December 202 1
6-7 April 2022 (Board Retreat )
22 -23 June 2022
7-8 D ecember 20 22 ---
Brend a Killen , Directo r, Governance and Secre tary t o the Board, +41 22 9 09 6 680, bkill en @gavi.org
Jo anne Goetz , Head, Governance, + 41 22 909 6544, jgoetz@gavi.o rg
Please no te that th e Board meeting w ill be recorded. This r ecording will be used as an aid to minute the meeting .
A transcr iptio n of the fu ll proceedings will not normally be made. Shou ld a transcription be made it wil l be us ed
only as an aid to minute the meeti ng .

Board -2021-Mtg -3-Doc 00a




G avi Alliance Board Meeting
28 September 202 1
Virtual Meeting

Tues day 28 September : 14.00-18.30 Geneva Time
Quor um: 14

Document list

No. Document
00a Document list
00b Agenda
01a Declarations of interest
02 CEO?s Report - To follow
03 Strat egy, Programmes and Partnerships: Progress, Risks and Challenges - No paper
04 a COVAX: Key Strategic Issues
04b COVAX : Resource Mobilisa tion Update
05 Closing remarks ? No paper

Board -2021 -Mtg -3-Doc 05 1
Report to the Board
28 September 20 21

















SUBJECT: CLOSING REMARKS
Agenda item: 05
No paper

1



Board -2021 -Mtg -3-Doc 04b

Section A: Summary
This paper presents the fundraising status of the Gavi COVAX Advance Market
Commitment (COVAX AMC) since its inception and the outcomes that are being
achieved with that funding and other instruments. It outlines plans for further
support for the COVAX Fac ility strategy for 2022 pursuant to the WHO Global
Vaccination Strategic Vision. It highlights the need for continued and immediate
grant financing (donor funding) as a critical step to guarantee increased access to
doses. It also illustrates the important complementary roles of dose sharing and
leveraging countries? domestic resources, supported by multilateral development
bank (MDB) funding, in providing timely access to doses, and presents some
preliminary resource mobilisation scenarios.
Section B: Reso urce mobilisation update
1. Fundraising update
1.1. To date, US$ 9.8 billion has been pledged to the Gavi COVAX AMC (see
Annex A). This financing enables the purchase of 1.7 billion COVID -19
vaccine doses benefiting 92 low and lower middle income economies
(COVAX AMC92 countries). In addition, US$ 800 million has been mobilised
to support delivery in countries.
1.2. The fundraising approach for the COVAX AMC as an innovative financing
mechanism has evolved flexibly over time to respond ambitiously to an
ever -changing global environment, pandemic trajectory and vaccine
landscape. The fundraising strategy has been built on leveraging three key
sources of financing: sovereign and private donors, capital markets and
country financing (including MDB funds). It has also criti cally relied on a
range of innovative instruments and mechanisms to facilitate early financing
and supply, including leveraging the International Finance Facility for
Immunisation (IFFIm) and crafting new frontloading facilities.
1.3. In a first phase starting with a G20 call in April 2020 for an international
collaboration to tackle the pandemic, the COVAX AMC was launched in
June 2020 at the UK -hosted Global Vaccine Summit to frontload immediate
financing to encourage vaccine development and reserve access to AMC
countries. Initial funding of US$ 500 million for lower income countries for
the COVAX AMC was pledged by donors including by drawing upon
SUBJECT: COVAX RESOURCE MOBILISATION UPDATE
Agenda item: 04b
Category: For Information
Report to the Board
28 September 2021

1 1


?
Re port to the Board

Board -2021 -Mtg -3-Doc 04b-Annex B
Classified as Internal
Annex B : Dose Donation to COVAX